https://orcid.org/0000-0001-6253-1833
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Background
The only causal treatment for allergic rhinitis (AR) is allergen immunotherapy (AIT) including personalized liquid sublingual AIT (SLIT). We present the methodology for establishing the EfficAPSI cohort to further evaluate the real-life effectiveness and use of SLIT liquid.
Research design and methods
The EfficAPSI cohort was constituted by deterministic linkage of Stallergenes Greer dispensing and nationwide French healthcare insurance system (SNDS) databases. Data from 2006 to 2018 were extracted. All patients who initiated Stallergenes Greer SLIT liquid between 2010 and 2013 were considered as exposed and those dispensed with AR symptomatic treatment only as control. To limit the impact of confounding, the models will be weighted using the inverse probability of treatment weighting (IPTW).
Results
A total of 445,574 patients were included; median age was 38 years; 59.1% were female. Exposed patients (n = 112,492) were significantly younger, more frequently males, and less likely to have comorbidities than controls (n = 333,082). After IPTW, patients’ characteristics from both groups were similar.
Conclusions
To date, the EfficAPSI cohort has the largest number of person-years of follow-up in the field of AIT. The completeness of the data allows to evaluate SLIT liquid effectiveness with rigorous methodology, leading to important insights on personalized medicine in real-life.
Declaration of interest
Financial and competing interests disclosure: P Devillier reports fees for advisory boards, lectures, consulting, or support for attending meetings from ALK-Abelló, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, IQVIA, Menarini, Mylan/Meda Pharma, Procter & Gamble, Stallergenes Greer and Viatris; M Molimard reports fees for consulting from ALK-Abelló, Novartis and Stallergenes Greer; JF Bergmann reports fees for advisory boards and consulting from Amgen, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, IQVIA, Janssen, Lilly, Novartis, Pfizer, Sanofi, Roche and Takeda;
A Gouverneur, J Vadel and C Collin are employees of IQVIA; L Girard and S Scurati are employees of Stallergenes Greer; P Demoly reports fees for research, teaching or consulting purposes from ALK-Abelló, AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Puressentiel, Stallergenes Greer, ThermoFisherScientific, Viatris and Zambon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have received an honorarium from Expert Opinion on Drug Metabolism and Toxicology for their review work but have no other relevant financial relationships to disclose.
Author contributions
All authors were involved in the conception and design, A Gouverneur, J Vadel and C Collin in analysis, all authors in the interpretation of the data; A Gouverneur, J Vadel and C Collin in drafting of the paper or revising it critically for intellectual content; all authors approved the final version of the manuscript; and all authors are agreeing to be accountable for all aspects of the work.
Geolocation information
France, Europe
Data availability statement
According to the principles of data protection and French regulations, the authors cannot publicly release the data from the ‘Système National des Données de Santé’ (SNDS). However, any person or structure, public or private, for-profit or nonprofit can access SNDS data upon authorization from the ‘Commission Nationale de l’Informatique et des Libertés’ (i.e., the French Data Protection Office) to carry out a study, research, or an evaluation of public interest (https://www.snds.gouv.fr).
Supplementary material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/1744666X.2023.2294040.